| Autor: |
NACS, Wong, Gonzalez D, Salto-Tellez M, Butler R, Diaz-Cano, Salvador J., M, Ilyas, Newman W, Shaw E, Taniere P, Walsh SV |
| Předmět: |
|
| Zdroj: |
Europe PubMed Central |
| Popis: |
Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of antiepidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
